Европска Унија - Летонски - EMA (European Medicines Agency)

mylan ireland limited - lenalidomide - multiple mieloma - imūnsupresanti - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Европска Унија - Летонски - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - imūnsupresanti - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš neārstētiem multiplā mieloma, kas nav tiesīgi transplantātu. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Европска Унија - Летонски - EMA (European Medicines Agency)

nova laboratories ireland limited - azatioprīns - transplanta noraidīšana - imūnsupresanti - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Европска Унија - Летонски - EMA (European Medicines Agency)

bayer ag - riociguat - hipertensija, plaušu slimība - antihypertensives for pulmonary arterial hypertension - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efektivitāte ir redzams pao iedzīvotājiem, tostarp aetiologies, idiopātiska vai iedzimtības pao, vai arī pao, kas saistīta ar saistaudu slimības. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Европска Унија - Летонски - EMA (European Medicines Agency)

teva b.v. - salmeterol, flutikazonu propionāts - pulmonary disease, chronic obstructive; asthma - zāles obstruktīvu elpceļu slimību, - airexar spiromax ir indicēts lietošanai tikai pieaugušajiem no 18 gadu vecuma. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. hroniskas obstruktīvas plaušu slimības (hops)airexar spiromax ir norādīts simptomātiska ārstēšana pacientiem ar hops, ar fev1.

Европска Унија - Летонски - EMA (European Medicines Agency)

mylan pharmaceuticals limited - atazanavir (as sulfate) - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - atazanavir mylan, co-vienīgi ar mazu devu ritonavir, ir indicēts, lai ārstētu hiv-1 inficētiem pieaugušajiem un pediatrijas pacientiem 6 gadu vecuma un vecākiem, kopā ar citiem antiretrovīrusu zāles. pamatojoties uz pieejamo virusoloģijas un klīniskajiem datiem no pieaugušo pacientu, nekādu labumu, ir paredzams, ka pacientiem ar celmi, kas ir izturīgi pret vairākiem proteāzi inhibitori (≥ 4 pi mutācijas). no bērniem vecumā no 6 līdz 18 gadiem ir pieejami ļoti ierobežoti dati. izvēle atazanavir mylan attieksmi pieredzējuši pieaugušajiem un pediatrijas pacientiem, kas būtu balstīta uz individuāliem vīrusu rezistences pārbaudi un pacienta ārstēšanas vēsture.

Европска Унија - Летонски - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - pemetrekseda dinātrija hemipentahidrāts - carcinoma, non-small-cell lung; mesothelioma - antineoplastiski līdzekļi - malignant pleural mesothelioma ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ciambra ir norādīts kā monotherapy uzturēšanas apstrāde vietas papildu vai metastātiska nav maza šūnu plaušu vēzis, izņemot galvenokārt plakanšūnu histoloģija pacientiem, kuru slimība nav progresējusi tūlīt pēc platīna ķīmijterapiju. ciambra ir norādīts kā monotherapy otrās līnijas ārstēšana pacientiem ar lokāli papildu vai metastātiska nav maza šūnu plaušu vēzis, izņemot galvenokārt plakanšūnu histoloģiju.

Европска Унија - Летонски - EMA (European Medicines Agency)

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiskie līdzekļi - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Европска Унија - Летонски - EMA (European Medicines Agency)

novartis europharm limited - sekukinumabs - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imūnsupresanti - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriātisko arthritiscosentyx, atsevišķi vai kombinācijā ar metotreksātu (mtx), ir indicēts, lai ārstētu aktīvo psoriātiskā artrīta ārstēšanai pieaugušiem pacientiem, ja atbilde uz iepriekšējo slimību modificējošiem anti reimatisko narkotiku (dmard) terapija ir bijusi nepietiekama. aksiālie spondyloarthritis (axspa), ankilozējošais spondilīts (as, radiogrāfisko aksiālie spondyloarthritis)cosentyx ir indicēts, lai ārstētu aktīvo ankilozējošā spondilīta pieaugušajiem, kuri atbildēja nepareizi uz parasto terapiju. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Европска Унија - Летонски - EMA (European Medicines Agency)

merck sharp & dohme b.v. - indinavir sulfāts ethanolate - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - crixivan tiek indicēts kombinācijā ar antiretrovīrusu nukleozīdu analogiem hiv-1 inficētiem pieaugušajiem.